Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
1998-12-4
|
| pubmed:abstractText |
Serial brain MRI scanning is widely used for assessing multiple sclerosis disease activity in the evaluation of new therapies. Traditionally, the net change in T2-weighted lesion volume between paired scans has been used as a measure of disease progression and as a secondary endpoint in definitive clinical trials. However, as the net change in T2-weighted lesion volume reflects only the difference between new and resolved T2-weighted lesions, this measure significantly under-represents the total T2-weighted lesion activity. Difference images produced by subtracting labelled T2-weighted lesion volumes from serial registered T2-weighted scans allows separate measurements of individual volumes of new and resolving T2-weighted lesions, which may reflect underlying disease activity more sensitively. We generated T2-weighted differences images to define T2-weighted lesion changes over 1 year for 19 patients with relapsing multiple sclerosis. The mean new T2-weighted lesion volume change was three times greater than the mean net T2-weighted lesion volume change over the study period. New T2-weighted lesion volumes were more strongly correlated with T1-weighted gadolinium-enhancing lesion volumes (r = 0.72, P = 0.001) than were the net T2-weighted lesion volume changes (r = 0.45, P = 0.01). Baseline T2-weighted lesion volume was more highly correlated with new T2-weighted lesion volumes (r = 0.89, P < 0.0001) than with net T2-weighted lesion change (r = 0.47, P < 0.001). There was a trend for patients who showed sustained clinical progression over the year to have a greater new T2-weighted lesion volume than those who did not. This difference was not seen with net T2-weighted lesion volume change. T2-weighted lesion difference images should provide an additional and sensitive tool for monitoring disease activity in multiple sclerosis. Independent definition of new and resolving T2-weighted lesion volumes also offers the potential for discrimination of the relative effects of experimental therapies on new inflammatory activity from the effects on oedema resolution and lesion repair.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0006-8950
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
121 ( Pt 11)
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
2095-102
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:9827769-Adult,
pubmed-meshheading:9827769-Brain,
pubmed-meshheading:9827769-Disease Progression,
pubmed-meshheading:9827769-Female,
pubmed-meshheading:9827769-Gadolinium,
pubmed-meshheading:9827769-Humans,
pubmed-meshheading:9827769-Magnetic Resonance Imaging,
pubmed-meshheading:9827769-Male,
pubmed-meshheading:9827769-Middle Aged,
pubmed-meshheading:9827769-Multiple Sclerosis,
pubmed-meshheading:9827769-Recurrence,
pubmed-meshheading:9827769-Regression Analysis,
pubmed-meshheading:9827769-Statistics, Nonparametric
|
| pubmed:year |
1998
|
| pubmed:articleTitle |
Defining multiple sclerosis disease activity using MRI T2-weighted difference imaging.
|
| pubmed:affiliation |
Centre for Functional Magnetic Resonance Imaging of the Brain, John Radcliffe Hospital, Headington, UK.
|
| pubmed:publicationType |
Journal Article
|